Clinical question of the day
In patients with non-dialysis–dependent CKD and anemia, how does erythropoetin treatment targeting a hemoglobin >13.5 g/dL compare with a hemoglobin >11.3 g/dL in reducing CV events including death, MI, hospitalizations for CHF, and stroke?